BDR Pharma Says BMS Misleads Delhi High Court Over Sprycel CL
This article was originally published in PharmAsia News
An India drug maker seeking a compulsory license to market a generic of a Bristol-Myers Squibb's Sprycel (dasatinib) cancer drug accused the U.S. firm of lying to the Delhi High Court over the status of BDR Pharma's application.
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.